Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies

Abstract The tumor microenvironment (TME) represents a metabolic battleground where immune cells and cancer cells vie for essential nutrients, ultimately influencing antitumor immunity and treatment outcomes. Recent advancements have shed light on how the metabolic reprogramming of immune cells, inc...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruoli Wang, Jincheng Zhuang, Qi Zhang, Wantao Wu, Xinrui Yu, Hao Zhang, Zongyi Xie
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Experimental Hematology & Oncology
Subjects:
Online Access:https://doi.org/10.1186/s40164-025-00689-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849343971308863488
author Ruoli Wang
Jincheng Zhuang
Qi Zhang
Wantao Wu
Xinrui Yu
Hao Zhang
Zongyi Xie
author_facet Ruoli Wang
Jincheng Zhuang
Qi Zhang
Wantao Wu
Xinrui Yu
Hao Zhang
Zongyi Xie
author_sort Ruoli Wang
collection DOAJ
description Abstract The tumor microenvironment (TME) represents a metabolic battleground where immune cells and cancer cells vie for essential nutrients, ultimately influencing antitumor immunity and treatment outcomes. Recent advancements have shed light on how the metabolic reprogramming of immune cells, including macrophages, T cells, and DCs, determines their functional polarization, survival, and interactions within the TME. Factors such as hypoxia, acidosis, and nutrient deprivation drive immune cells toward immunosuppressive phenotypes, while metabolic interactions between tumors and stromal cells further entrench therapeutic resistance. This review synthesizes new insights into the metabolic checkpoints that regulate immune cell behavior, focusing on processes like glycolysis, oxidative phosphorylation (OXPHOS), lipid oxidation, and amino acid dependencies. We emphasize how metabolic enzymes (e.g., IDO1, ACLY, CPT1A) and metabolites (e.g., lactate, kynurenine) facilitate immune evasion, and we propose strategies to reverse these pathways. Innovations such as single-cell metabolomics, spatial profiling, and AI-driven drug discovery are transforming our understanding of metabolic heterogeneity and its clinical implications. Furthermore, we discuss cutting-edge therapeutic approaches—from dual-targeting metabolic inhibitors to biomaterial-based delivery systems—that aim to reprogram immune cell metabolism and enhance the effectiveness of immunotherapy. Despite the promise in preclinical studies, challenges persist in translating these findings to clinical applications, including biomarker validation, metabolic plasticity, and interpatient variability. By connecting mechanistic discoveries with translational applications, this review highlights the potential of immunometabolic targeting to overcome resistance and redefine precision oncology.
format Article
id doaj-art-05dd74e3b6f44f7082fcea15c170ca7c
institution Kabale University
issn 2162-3619
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series Experimental Hematology & Oncology
spelling doaj-art-05dd74e3b6f44f7082fcea15c170ca7c2025-08-20T03:42:48ZengBMCExperimental Hematology & Oncology2162-36192025-07-0114115410.1186/s40164-025-00689-6Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapiesRuoli Wang0Jincheng Zhuang1Qi Zhang2Wantao Wu3Xinrui Yu4Hao Zhang5Zongyi Xie6Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical UniversityDepartment of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical UniversityDepartment of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical UniversityDepartment of Thyroid and Breast Surgery, The Second Affiliated Hospital, Chongqing Medical UniversityDepartment of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical UniversityDepartment of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical UniversityDepartment of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical UniversityAbstract The tumor microenvironment (TME) represents a metabolic battleground where immune cells and cancer cells vie for essential nutrients, ultimately influencing antitumor immunity and treatment outcomes. Recent advancements have shed light on how the metabolic reprogramming of immune cells, including macrophages, T cells, and DCs, determines their functional polarization, survival, and interactions within the TME. Factors such as hypoxia, acidosis, and nutrient deprivation drive immune cells toward immunosuppressive phenotypes, while metabolic interactions between tumors and stromal cells further entrench therapeutic resistance. This review synthesizes new insights into the metabolic checkpoints that regulate immune cell behavior, focusing on processes like glycolysis, oxidative phosphorylation (OXPHOS), lipid oxidation, and amino acid dependencies. We emphasize how metabolic enzymes (e.g., IDO1, ACLY, CPT1A) and metabolites (e.g., lactate, kynurenine) facilitate immune evasion, and we propose strategies to reverse these pathways. Innovations such as single-cell metabolomics, spatial profiling, and AI-driven drug discovery are transforming our understanding of metabolic heterogeneity and its clinical implications. Furthermore, we discuss cutting-edge therapeutic approaches—from dual-targeting metabolic inhibitors to biomaterial-based delivery systems—that aim to reprogram immune cell metabolism and enhance the effectiveness of immunotherapy. Despite the promise in preclinical studies, challenges persist in translating these findings to clinical applications, including biomarker validation, metabolic plasticity, and interpatient variability. By connecting mechanistic discoveries with translational applications, this review highlights the potential of immunometabolic targeting to overcome resistance and redefine precision oncology.https://doi.org/10.1186/s40164-025-00689-6Tumor microenvironmentImmune cells metabolismMetabolic reprogrammingImmunotherapy resistanceTherapeutic targeting
spellingShingle Ruoli Wang
Jincheng Zhuang
Qi Zhang
Wantao Wu
Xinrui Yu
Hao Zhang
Zongyi Xie
Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies
Experimental Hematology & Oncology
Tumor microenvironment
Immune cells metabolism
Metabolic reprogramming
Immunotherapy resistance
Therapeutic targeting
title Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies
title_full Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies
title_fullStr Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies
title_full_unstemmed Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies
title_short Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies
title_sort decoding the metabolic dialogue in the tumor microenvironment from immune suppression to precision cancer therapies
topic Tumor microenvironment
Immune cells metabolism
Metabolic reprogramming
Immunotherapy resistance
Therapeutic targeting
url https://doi.org/10.1186/s40164-025-00689-6
work_keys_str_mv AT ruoliwang decodingthemetabolicdialogueinthetumormicroenvironmentfromimmunesuppressiontoprecisioncancertherapies
AT jinchengzhuang decodingthemetabolicdialogueinthetumormicroenvironmentfromimmunesuppressiontoprecisioncancertherapies
AT qizhang decodingthemetabolicdialogueinthetumormicroenvironmentfromimmunesuppressiontoprecisioncancertherapies
AT wantaowu decodingthemetabolicdialogueinthetumormicroenvironmentfromimmunesuppressiontoprecisioncancertherapies
AT xinruiyu decodingthemetabolicdialogueinthetumormicroenvironmentfromimmunesuppressiontoprecisioncancertherapies
AT haozhang decodingthemetabolicdialogueinthetumormicroenvironmentfromimmunesuppressiontoprecisioncancertherapies
AT zongyixie decodingthemetabolicdialogueinthetumormicroenvironmentfromimmunesuppressiontoprecisioncancertherapies